Chemokine News and Research

RSS
Chemokines are a family of small cytokines, or proteins secreted by cells. Proteins are classified as chemokines according to shared structural characteristics such as small size (they are all approximately 8-10 kilodaltons in size), and the presence of four cysteine residues in conserved locations that are key to forming their 3-dimensional shape.
Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

PS-targeting antibodies can block HIV virus from entering into certain blood cells

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx undertakes Phase II clinical trial of CCX140

Microglia contribute to loss of neurons linked with Alzheimer's disease

Microglia contribute to loss of neurons linked with Alzheimer's disease

Blocking GM-CSF could reduce inflammation and deleterious effects of cigarette smoke exposure

Blocking GM-CSF could reduce inflammation and deleterious effects of cigarette smoke exposure

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Study shows CEL-2000 vaccine blocks RA progression in mice

Study shows CEL-2000 vaccine blocks RA progression in mice

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

Study on the role of MCP-1 in obese patients with pancreatic cancer

Study on the role of MCP-1 in obese patients with pancreatic cancer

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Elevated cytokine levels are early indicator of rheumatoid arthritis

Elevated cytokine levels are early indicator of rheumatoid arthritis

Babraham Institute research may lead to new means of making purified T cells

Babraham Institute research may lead to new means of making purified T cells